Table 1.
Clinical and biochemical parameters of all the 6 subjects
| S No. | Primary IST | Indication |
Baseline |
Second month completion |
Fourth month completion |
Sixth month completion |
F/U (mo) |
Last follow-up |
aPLA2R (RU/ml) |
RTX |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UP (g/d) |
Sr Alb (g/dl) |
UP (g/d) |
Sr Alb (g/dl) |
UP (g/d) |
Sr Alb (g/dl) |
UP (g/d) |
Sr Alb (g/dl) |
UP (g/d) |
Sr Alb (g/dl) |
Pre-RTX | Post-RTX | Additional doses | Time (mo) |
||||
| 1 | cCTX/GC | Relapse | 8.98 | 3.10 | 3.88 | 3.10 | 3.60 | 3.20 | 1.03 | 3.60 | 14 | 0.701 | 3.70 | 73.11 | 4.528 | 02 | 03, 08 |
| 2 | cCTX/GC | Resistant | 6.20 | 1.40 | 1.20 | 5.50 | 1.25 | 5.20 | 3.00 | 2.10 | 12 | 3.20 | 3.10 | 121.59 | 93.99 | 03 | 01, 04, 05 |
| 3 | TAC | Intolerant | 2.30 | 1.30 | 2.90 | 3.13 | 2.86 | 3.42 | 1.92 | 4.32 | 15 | 0.29 | 4.32 | 28.87 | 2.00 | 04 | 04, 09, 12, 15 |
| 4 | cCTX/GC | Resistant | 5.50 | 3.50 | 2.90 | 3.90 | 3.10 | 3.20 | 3.20 | 4.40 | 13 | 1.13 | 4.34 | 111.87 | 2.00 | 02 | 02, 06 |
| 5 | cCTX/GC | Resistant | 31.00 | 1.68 | 16.220 | 1.59 | 3.80 | 1.98 | 19.60 | 1.83 | 10 | 8.80 | 3.50 | 27.13 | 79.76 | 02 | 01, 04 |
| 6 | cCTX/GCa | Resistant | 18.41 | 1.60 | 15.03 | 1.30 | 9.58 | 2.63 | 8.00 | 2.00 | 14 | 3.13 | 3.30 | 59.89 | 56.79 | 03 | 02, 05, 06 |
Mean time to CD19 repletion was 2.17 ± 1.17 (range 1–4) mo and all the subjects received further therapy (median doses 2.5, range 2–4).
aPLA2R, m-type phospholipase A2 receptor antibody; cCTX/GC, cyclical cyclophosphamide and steroids; F/U, follow-up; IST, immunosuppressive therapy; RTX, rituximab; Sr Alb, serum albumin; TAC, tacrolimus; UP, urine protein.
a
Patient developed upper respiratory tract infection, which was successfully managed with oral antibiotics.